# PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review

**Authors:** Maria Mazzitelli, Olivia Bargiacchi, Maria Aurora Carleo, Andrea Giacomelli, Camilla Muccini, Lucia Taramasso, Marcello Trizzino, Antonella Cingolani

PMC · DOI: 10.3390/v18010007 · Viruses · 2025-12-19

## TL;DR

This review examines how patient-reported outcomes (PROs) are used in HIV care for people on dual antiretroviral therapies, highlighting their benefits and challenges.

## Contribution

The paper provides a narrative review of PROs in dual HIV regimens, emphasizing their role in clinical decision-making and care optimization.

## Key findings

- Dual regimens show high treatment satisfaction and stable or improved quality of life.
- Long-acting injectables raise concerns about injection-site reactions and visit burden.
- Real-world data on PROs are inconsistent due to varied assessment methods and tools.

## Abstract

Background: With modern antiretroviral regimens, durable viral suppression is now achieved in most people with HIV (PWH), whose life expectancy approaches that of the general population. Consequently, recent guidelines emphasise, beyond virological and immunological control, health-related quality of life and patient-reported outcomes (PROs) as targets of HIV care, including for dual regimens. Methods: We conducted a narrative review of clinical trials and observational studies evaluating PROs in adults treated with dual antiretroviral therapies, either oral or long-acting injectable. We also examined guideline documents and implementation studies addressing the role, feasibility, and interpretation of PROs in routine HIV care. Results: Trials of dual regimens reported high treatment satisfaction, convenience, and stable or improved quality of life, with some concerns related to injection-site reactions and visit burden for long-acting formulations. Emerging real-world data broadly confirm these findings but remain heterogeneous, with variability in instruments, assessment timing, and analytic approaches, limiting comparability and clinical use. Conclusions: PROs may support shared decision-making and optimise the use of dual therapies in PWH, but their uptake in clinical practice is still limited. Standardised tools, clearer interpretative frameworks, and pragmatic implementation strategies are needed to better integrate PROs into everyday HIV care.

## Full-text entities

- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12846361/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12846361/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12846361/full.md

---
Source: https://tomesphere.com/paper/PMC12846361